Moderna thanks the Portuguese company GenIbet Biopharmaceuticals for its crucial role in developing the mRNA technology used in the covid-19 vaccine. 

In 2015, Genibet partnered with Moderna to produce the first 15 mRNA batches and became Moderna’s mRNA manufacturer and storer. Between 2015 and 2019, Moderna used the mRNA batches produced by GenIbet in several clinical trials. Five years later, this technology’s study allowed Moderna to develop its covid-19 vaccine, the first using mRNA technology.

The recognition of the Portuguese company’s role from the North American pharmaceutical arrived in Portugal through an email signed by its executive president, Stéphane Bancel.

mRNA is a single-stranded molecule of RNA that is nuclear for the covid-19 vaccine. The Pfizer vaccine also uses this technology. Moderna and Pfizer vaccines contain genetic material from the new coronavirus that gives instructions (through mRNA) to our cells to produce a specific virus protein. When the human immune system identifies this protein as foreign to the body, antigens (the vaccine) are created and will fight SARS-Cov-2 in case of contagion.

mRNA is one of the new ways to design vaccines more effectively and safely. The great advantage of this technology is to allow vaccines to be made in an almost synthetic way, not requiring to obtain the use of cells. It reduces costs and introduces speed in the production process.

Portugal is a country open to business, ready to provide the first-class R&D to the world.

Visit genibet.eu


If you are interested in this company and its products or services and want to know more,  please fill out the below form. We will get back to you shortly.